Pharmaceutical

Balancing a Kidney Diet: Optimizing Nutrition Through Personalization

NORTHAMPTON, MA / ACCESS Newswire / December 22, 2025 / DaVita:For individuals managing chronic kidney disease (CKD), dietary choices significantly…

13 hours ago

Ovation Science Sees Expanded Opportunities for Its Topical Products Following U.S. Cannabis Rescheduling

VANCOUVER, BC AND LAS VEGAS, NV / ACCESS Newswire / December 22, 2025 / Ovation Science Inc. (CSE:OVAT)(OTC PINK:OVATF) ("Ovation"…

13 hours ago

1933 Industries Issues Final Reminder to 2024 Debenture Holders: December 22 Is the Deadline to Convert

VANCOUVER, BC / ACCESS Newswire / December 22, 2025 / 1933 Industries Inc. (the "Company" or "1933 Industries") (CSE:TGIF)(OTCID:TGIFF) issues…

13 hours ago

Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics Platform

The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist,…

13 hours ago

1933 Industries Achieves Positive Income in Q1 2026, Marking Third Consecutive Profitable Quarter

VANCOUVER, BC / ACCESS Newswire / December 22, 2025 / 1933 Industries Inc. (the "Company" or "1933 Industries") (CSE:TGIF)(OTCID:TGIFF), a…

13 hours ago

CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies

-Four autoimmune patients treated to date demonstrate deep B-cell depletion sustained for at least 28 days; initial efficacy data suggest…

13 hours ago

SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA

U.S. Naloxone Market: ~$154 million in annual sales and 9.3 million units annually COMMACK, NY, Dec. 22, 2025 (GLOBE NEWSWIRE)…

13 hours ago

CoRegen Appoints Globally Recognized Surgeon-Scientist Bert O’Malley Jr. to its Board of Directors

HOUSTON, Dec. 22, 2025 (GLOBE NEWSWIRE) -- CoRegen, Inc., a biopharmaceutical company pursuing novel treatments for patients impacted by some…

13 hours ago

ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer

Firmonertinib has the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, chemo-free monotherapyALPACCA…

13 hours ago

ORYZON Expands Global Patent Protection for Iadademstat with Grant Decision in Japan Covering Combinations with PD-1/PD-L1 Inhibitors

Key combination for the treatment of Small Cell Lung CancerMADRID and CAMBRIDGE, Mass., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Oryzon…

13 hours ago